Compare ARK Genomic Revolution ETF (ARKG) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs WD 40 Company — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while WD 40 Company trades at $265 (market cap $3.56B). The key difference: WD 40 Company pays a 1.54% dividend while ARK Genomic Revolution ETF pays none, and WD 40 Company is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | WDFC | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $264.91 |
52-Week Low | $23.09 | $187.52 |
Market Cap | — | $3.56B |
Enterprise Value | — | $3.61B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
WDFC stock trades at $264.91, up 10.65% ($25.49) on strong Q2 2026 earnings that beat estimates with EPS of $2.33 versus $1.58 expected. The technical outlook is bullish with support at $237 and resistance at $245. Fundamentals show robust revenue growth to $675M in 2026 and a net income margin of 13.22%, though valuation multiples like a P/E of 40.28 appear elevated. Positive media coverage highlights the company's strong brand and consistent performance.
The outlook remains positive given earnings beats and brand strength, but high valuation and margin pressure from input costs pose risks. Analyst consensus is mostly neutral with 71% hold ratings, suggesting cautious optimism. The stock offers stability but may face headwinds if growth slows or costs rise further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
